EU Approval Of Mesenchymal Stromal Cell Therapy Manufacturing Protocol Using nLiven Human Platelet Lysate For A Phase 1B Clinical Trial
Sexton Biotechnologies and CCMI Galway collaborative effort leads to approval by EU regulatory authorities for the use of nLiven PR in the expansion of an allogeneic MSC therapeutic product to address corneal transplant rejection
Read More